Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients | Zendy

J. Verhelst | Zendy; AM Pedroncelli | Zendy; Roger Abs | Zendy; M Montini | Zendy; MV Vandeweghe | Zendy; G Albani | Zendy; Dominique Maiter | Zendy; MD Pagani | Zendy; J.-J. Legros | Zendy; D. Gianola | Zendy; M Bex | Zendy; Kris Poppe | Zendy; Jean Mockel | Zendy; G. Pagani | Zendy

AI Assistant Blog Pricing

Open Access

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

Author(s) -

J. Verhelst,

AM Pedroncelli,

Roger Abs,

M Montini,

MV Vandeweghe,

G Albani,

Dominique Maiter,

MD Pagani,

J.-J. Legros,

D. Gianola,

M Bex,

Kris Poppe,

Jean Mockel,

G. Pagani

Publication year - 2000

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje.0.1430577

Subject(s) - acromegaly , lanreotide , medicine , octreotide , somatostatin , endocrinology , gastroenterology , prospective cohort study , hormone , growth hormone

Slow-release (SR) lanreotide is a long-acting somatostatin analog that has been developed in order to overcome the inconvenience of multiple daily subcutaneous injections of octreotide, required for metabolic control in acromegaly. Lanreotide SR has been found to be well tolerated and effective in reducing GH and IGF-I levels but clinical data are still limited compared with those with subcutaneous octreotide treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog